SC1-PM-08-2017
SC1-PM-08-2017
10 projects · €60,500,512 total EU contribution (project-level) · 100 participating organizations · 18 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€60,500,512
Countries active
Participant organizations by country (headquarters in CORDIS).
- Italy (18)
- Germany (17)
- UK (14)
- France (11)
- Netherlands (10)
- Spain (8)
- BE (7)
- IL (2)
- NO (2)
- PT (2)
- US (2)
- AT (1)
- AU (1)
- CH (1)
- DK (1)
- HU (1)
- IE (1)
- PL (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- UNEW4 projects · UK
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS3 projects · FR
- Leiden University Medical Center2 projects · NL
- GENETHON2 projects · FR
- CFE2 projects · DE
- EUROPEAN CYSTIC FIBROSIS SOCIETY2 projects · DK
- GENOSAFE SAS2 projects · FR
- KU Leuven2 projects · BE
- LMU MUENCHEN2 projects · DE
- MHH2 projects · DE
- OSPEDALE PEDIATRICO BAMBINO GESU2 projects · IT
- OSR2 projects · IT
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Stem-cell based gene therapy for recombination deficient SCID (RECOMB) RECOMB · 755170 | H2020 | €5,990,460 | €0 | Details |
Personalised Treatment For Cystic Fibrosis Patients With Ultra-rare CFTR Mutations (and beyond) HIT-CF · 755021 | H2020 | €6,701,365 | €0 | Details |
Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome CureCN · 755225 | H2020 | €6,249,104 | €4,049,250 | Details |
SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease CARAMBA · 754658 | H2020 | €6,097,875 | €0 | Details |
Transfer of multivirus-specific T-cells following transplantation TRACE · 755005 | H2020 | €6,000,000 | €388,750 | Details |
A pivotal phase IIb clinical trial of inhaled alginate oligosaccharide (OligoG) for cystic fibrosis OligoGpivotalCF · 755234 | H2020 | €6,013,749 | €2,501,250 | Details |
Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) TUDCA-ALS · 755094 | H2020 | €5,596,928 | €352,281 | Details |
Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB UshTher · 754848 | H2020 | €5,998,516 | €91,069 | Details |
A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma. CLINGLIO · 755179 | H2020 | €6,155,125 | €97,000 | Details |
Repurposing of carbamazepine for treatment of skeletal dysplasia MCDS-Therapy · 754825 | H2020 | €5,697,391 | €0 | Details |